TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Dialysis Strategies in Critically Ill Patients With Acute Renal Failure on the Intensive Care Unit
Brief Summary: The goal of the present study is the comparison of different dialysis strategies in critically ill patients with acute renal failure on the intensive care unit. Patients are treated with either continuous dialysis or hemofiltration. Outcome measures are death, restitution of renal function, days on ICU, hemodynamic stability, dialysis efficiency.


Options:
A: Arm Label: SLED; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Arm Label: CVVHD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Intervention Type: PROCEDURE; Name: Renal replacement therapy; Assigned to Arm(s): CVVHD, SLED
B: Arm Label: RCA Group; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation) | Arm Label: Heparin group; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin) | Intervention Type: DRUG; Name: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation); Assigned to Arm(s): RCA Group | Intervention Type: DRUG; Name: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin); Assigned to Arm(s): Heparin group
C: Arm Label: AN69ST; Type: EXPERIMENTAL; Interventions: Device: AN69ST hemofilter | Arm Label: AN69; Type: ACTIVE_COMPARATOR; Interventions: Device: AN69 hemofilter | Intervention Type: DEVICE; Name: AN69ST hemofilter; Assigned to Arm(s): AN69ST | Intervention Type: DEVICE; Name: AN69 hemofilter; Assigned to Arm(s): AN69
D: Arm Label: CVVH arm; Type: ACTIVE_COMPARATOR; Interventions: Other: RRT for acute kidney failure using the CVVH method | Arm Label: IHD arm; Type: ACTIVE_COMPARATOR; Interventions: Other: RRT for acute kidney failure using the IHD (intermittent HD) | Intervention Type: OTHER; Name: RRT for acute kidney failure using the CVVH method; Assigned to Arm(s): CVVH arm | Intervention Type: OTHER; Name: RRT for acute kidney failure using the IHD (intermittent HD); Assigned to Arm(s): IHD arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Dialysis Strategies in Critically Ill Patients With Acute Renal Failure on the Intensive Care Unit
Brief Summary: The goal of the present study is the comparison of different dialysis strategies in critically ill patients with acute renal failure on the intensive care unit. Patients are treated with either continuous dialysis or hemofiltration. Outcome measures are death, restitution of renal function, days on ICU, hemodynamic stability, dialysis efficiency.


Options:
A: Arm Label: Standard strategy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard strategy | Arm Label: Delayed strategy; Type: EXPERIMENTAL; Interventions: Procedure: Delayed strategy | Intervention Type: PROCEDURE; Name: Standard strategy; Assigned to Arm(s): Standard strategy | Intervention Type: PROCEDURE; Name: Delayed strategy; Assigned to Arm(s): Delayed strategy
B: Arm Label: SLED; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Arm Label: CVVHD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Intervention Type: PROCEDURE; Name: Renal replacement therapy; Assigned to Arm(s): CVVHD, SLED
C: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
D: Intervention Type: PROCEDURE; Name: renal replacement therapy (intermittent or continuous); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Dialysis Strategies in Critically Ill Patients With Acute Renal Failure on the Intensive Care Unit
Brief Summary: The goal of the present study is the comparison of different dialysis strategies in critically ill patients with acute renal failure on the intensive care unit. Patients are treated with either continuous dialysis or hemofiltration. Outcome measures are death, restitution of renal function, days on ICU, hemodynamic stability, dialysis efficiency.


Options:
A: Intervention Type: PROCEDURE; Name: renal replacement therapy (intermittent or continuous); Assigned to Arm(s): N/A
B: Arm Label: SLED; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Arm Label: CVVHD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Intervention Type: PROCEDURE; Name: Renal replacement therapy; Assigned to Arm(s): CVVHD, SLED
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous venvenous hemofiltration (CVVH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous venovenous hemodialysis (CVVHD) | Intervention Type: DEVICE; Name: Continuous venvenous hemofiltration (CVVH); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Continuous venovenous hemodialysis (CVVHD); Assigned to Arm(s): 2
D: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain
Brief Summary: To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from Diabetic Neuropathy.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine Hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre Randomised Trial of Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure
Brief Summary: This multicentre SHARF4 (Stuivenberg Hospital Acute Renal Failure) study aims to investigate outcome in patients with acute renal failure (ARF), stratified according to severity of disease (SHARF score) and randomised to different treatment options.

All adult patients with a serum creatinine \>2 mg/dl were included. Patients were stratified according to disease severity and those in need for RRT were randomised to intermittent (IRRT) or continuous renal replacement therapy (CRRT)


Options:
A: Arm Label: SLED; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Arm Label: CVVHD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Intervention Type: PROCEDURE; Name: Renal replacement therapy; Assigned to Arm(s): CVVHD, SLED
B: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h
C: Intervention Type: PROCEDURE; Name: renal replacement therapy (intermittent or continuous); Assigned to Arm(s): N/A
D: Arm Label: Early initiation of RRT; Type: EXPERIMENTAL; Interventions: Procedure: Renal Remplacement Therapy | Arm Label: Deferred RRT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal Remplacement Therapy | Intervention Type: PROCEDURE; Name: Renal Remplacement Therapy; Assigned to Arm(s): Deferred RRT, Early initiation of RRT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre Randomised Trial of Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure
Brief Summary: This multicentre SHARF4 (Stuivenberg Hospital Acute Renal Failure) study aims to investigate outcome in patients with acute renal failure (ARF), stratified according to severity of disease (SHARF score) and randomised to different treatment options.

All adult patients with a serum creatinine \>2 mg/dl were included. Patients were stratified according to disease severity and those in need for RRT were randomised to intermittent (IRRT) or continuous renal replacement therapy (CRRT)


Options:
A: Intervention Type: PROCEDURE; Name: renal replacement therapy (intermittent or continuous); Assigned to Arm(s): N/A
B: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care
C: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
D: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Eliminating Trachoma With Repeat Mass Drug Treatment
Brief Summary: The WHO has initiated a program to eliminate trachoma, blinding eye infection caused by Chlamydia trachomatis, in large part by mass distributions of oral azithromycin. The proposed study will determine the frequency and treatment target of community-wide mass antibiotic treatment. We will also study the impact of mass antibiotic distribution on antibiotic-resistance in pneumococcus.


Options:
A: Arm Label: A; Type: OTHER; Interventions: Drug: Mass treatment with oral azithromycin to an entire community | Arm Label: B; Type: OTHER; Interventions: Drug: Mass treatment with oral azithromycin to an entire community | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Mass treatment with oral azithromycin to an entire community | Arm Label: D; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: F; Type: OTHER; Interventions: Drug: Mass treatment with oral azithromycin to an entire community | Arm Label: G; Type: EXPERIMENTAL; Interventions: Drug: Mass treatment with oral azithromycin to an entire community | Intervention Type: DRUG; Name: Mass treatment with oral azithromycin to an entire community; Assigned to Arm(s): A, B, C, F, G
B: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo
C: Arm Label: ≥90% coverage with azithromycin target; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: 80%-89% coverage with azithromycin target; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: ≥90% coverage with azithromycin , treatment based; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: 80%-89% coverage with azithromycin : treatment based; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 80%-89% coverage with azithromycin target, ≥90% coverage with azithromycin target | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 80%-89% coverage with azithromycin : treatment based, ≥90% coverage with azithromycin , treatment based
D: Arm Label: J; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: K; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: L; Type: OTHER; Interventions: Drug: mass treatment with oral azithromycin | Arm Label: M; Type: OTHER; Interventions: Drug: mass treatment with oral azithromycin | Arm Label: N; Type: EXPERIMENTAL; Interventions: Drug: mass treatment with oral azithromycin | Arm Label: O; Type: EXPERIMENTAL; Interventions: Drug: mass treatment with oral azithromycin | Intervention Type: DRUG; Name: mass treatment with oral azithromycin; Assigned to Arm(s): L, M, N, O

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
Brief Summary: T-cell Non-Hodgkin's lymphomas are a group of cancers that are usually treated with chemotherapy, radiation therapy, or occasionally surgery. T-cell lymphomas are relatively uncommon and therefore not well studied. Treatment approaches are patterned after the more common B-cell lymphomas. T-cell lymphomas are more likely to relapse following standard therapy than are B-cell lymphomas. New therapies are needed for T-cell lymphomas. In this study, we will administer the drug called lenalidomide as a pill to patients with T-cell lymphoma. The goals are to determine if the drug can induce regression of the cancer, and to determine if the treatment is well tolerated in this patient group. This study will take place at six cancer centres across Canada.


Options:
A: Arm Label: KW-0761; Type: EXPERIMENTAL; Interventions: Biological: KW-0761 | Arm Label: Vorinostat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vorinostat | Intervention Type: BIOLOGICAL; Name: KW-0761; Assigned to Arm(s): KW-0761 | Intervention Type: DRUG; Name: Vorinostat; Assigned to Arm(s): Vorinostat
B: Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): N/A
C: Arm Label: Bexarotene and PUVA; Type: EXPERIMENTAL; Interventions: Drug: bexarotene, Drug: methoxypsoralen, Procedure: UV light therapy | Arm Label: PUVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: methoxypsoralen, Procedure: UV light therapy | Intervention Type: DRUG; Name: bexarotene; Assigned to Arm(s): Bexarotene and PUVA | Intervention Type: DRUG; Name: methoxypsoralen; Assigned to Arm(s): Bexarotene and PUVA, PUVA | Intervention Type: PROCEDURE; Name: UV light therapy; Assigned to Arm(s): Bexarotene and PUVA, PUVA
D: Arm Label: PUVA maintenance treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8-methoxypsoralen | Arm Label: No maintenance treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 8-methoxypsoralen; Assigned to Arm(s): PUVA maintenance treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PILOT-EBM: Patient Focused Intervention to Improve Long-term Adherence to Evidence Based Medications
Brief Summary: The purpose of this study is to evaluate the effectiveness of a program to help patients with heart disease stay on their heart medications.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: oral education & written tips for remembering medications, Device: pill box, Device: pocket medication card, Behavioral: sharing information with community pharmacist, Behavioral: Medication use evaluations by community pharmacist, Behavioral: informing physician if patient has stopped a medication, Behavioral: Routine discharge counseling, Other: Letter to physician/discharge summary | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Routine discharge counseling, Other: Letter to physician/discharge summary | Intervention Type: BEHAVIORAL; Name: oral education & written tips for remembering medications; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: pill box; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: pocket medication card; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: sharing information with community pharmacist; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Medication use evaluations by community pharmacist; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: informing physician if patient has stopped a medication; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Routine discharge counseling; Assigned to Arm(s): Intervention, Usual Care | Intervention Type: OTHER; Name: Letter to physician/discharge summary; Assigned to Arm(s): Intervention, Usual Care
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diabetes Peer Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Peer Counseling | Intervention Type: BEHAVIORAL; Name: Diabetes Peer Counseling; Assigned to Arm(s): Diabetes Peer Counseling
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Full drug coverage | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual coverage | Intervention Type: OTHER; Name: Full drug coverage; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual coverage; Assigned to Arm(s): 2
D: Arm Label: Pharmacist management; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical pharmacist-based intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical pharmacist-based intervention; Assigned to Arm(s): Pharmacist management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of the iStent trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing cataract.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: phacoemulsification alone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent Trabecular Micro-Bypass Stent | Intervention Type: PROCEDURE; Name: phacoemulsification alone; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: iStent Trabecular Micro-Bypass Stent; Assigned to Arm(s): 2
B: Arm Label: A--iStent plus Cataract Surgery; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent plus Cataract Surgery | Arm Label: B--Cataract Surgery Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract surgery only | Intervention Type: DEVICE; Name: iStent plus Cataract Surgery; Assigned to Arm(s): A--iStent plus Cataract Surgery | Intervention Type: PROCEDURE; Name: Cataract surgery only; Assigned to Arm(s): B--Cataract Surgery Only
C: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Glaucoma Surgery | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: cataract surgery only | Intervention Type: DEVICE; Name: Glaucoma Surgery; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: cataract surgery only; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicentre, Randomized, Double-blind Study To Assess The Efficacy And Safety Of Oral Sildenafil 20mg Tid Or Placebo When Added To Bosentan In The Treatment Of Subjects, Aged 18 Years And Above, With Pulmonary Arterial Hypertension (Pah)
Brief Summary: To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy.


Options:
A: Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): N/A
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bosentan, Other: Placebo | Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Bosentan, Drug: Sildenafil Citrate | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Sildenafil Citrate; Assigned to Arm(s): Active
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1

Answer: B